Cencora (NYSE:COR) has experienced a significant rise in the past five years, up by 193%. Following its Q4 announcement of fiscal 2024 earnings, the company's share price dipped 2.8%. However, there's been an increase of 13.2% and 16.6% YTD due to valuable assets that attract investors.
Heavyweight investors like
Walgreens Boots Alliance and
Mackenzie Financial Corp have manipulated their stakes in Cencora. While Walgreens has been reducing its interests, Mackenzie has expanded its position, buying an additional 7,266 shares. However, there were subsequent dips in the share price due to shifts in these major holdings.
Meanwhile, supply constraints on Anti-Obesity Drugs caused temporary falls in the Cencora stock. But successful contract renewals with Evernorth and a revised outlook have bolstered confidence creating optimism on the market. Cencora's
Q3 2024 earnings surpassed expectations and beat revenue estimates, signaling robust financial health. This far outweighed minor setbacks like the reported data breach in February.
Looking towards the future, Cencora's intrinsic value is estimated to be potentially 81% above its share price. Cencora continues to focus on growth and value segments, demonstrating robust financial fundamentals for long-term investors.
Cencora COR News Analytics from Wed, 30 Aug 2023 07:00:00 GMT to Fri, 04 Oct 2024 13:00:27 GMT -
Rating 7
- Innovation 6
- Rumor 4
